

NHS BOLTON CLINICAL COMMISSIONING GROUP – VIRTUAL MEETING

AGENDA ITEM NO:12.....

Date of Meeting:9th April 2021.....

TITLE OF REPORT:	COVID-19 Update to the Board	
AUTHOR:	Su Long, Accountable Officer Helen Wall, Clinical Director, Commissioning	
PRESENTED BY:	Su Long/Helen Wall	
PURPOSE OF PAPER: (Linking to Strategic Objectives)	To provide the CCG Board with an update on actions taken in the management of the ongoing COVID-19 pandemic. This month's report highlights the work progressed so far both nationally and locally on the implementation of the Covid 19 vaccination programme.	
LINKS TO CORPORATE OBJECTIVES (tick relevant boxes):	Deliver the outcomes in the Bolton Joint Health and Care Plan.	
	Ensure compliance with the NHS statutory duties and NHS Constitution.	√
	Deliver financial balance.	
	Regulatory Requirement.	
	Standing Item.	
RECOMMENDATION TO THE BOARD: (Please be clear if decision required, or for noting)	The Board is asked to note and discuss the attached report.	
COMMITTEES/GROUPS PREVIOUSLY CONSULTED:	Bolton COVID-19 Governance CCG Executive	
REVIEW OF CONFLICTS OF INTEREST:	N/A	
VIEW OF THE PATIENTS, CARERS OR THE PUBLIC, AND THE EXTENT OF THEIR INVOLVEMENT:	N/A	
EQUALITY IMPACT ASSESSMENT (EIA) COMPLETED & OUTCOME OF ASSESSMENT:	An Equality Impact section is included in the report.	


COVID-19 rate in Bolton



Bolton

Clinical Commissioning Group

Daily confirmed cases of COVID-19 for Bolton, with Pillar 1 and Pillar 2 cases inclusive



Better Bolton.

COVID-19 Vaccination Programme: Priority Groups set nationally by JCVI*

Cohorts 1-9 are now all being invited for their first dose

1. residents in a care home for older adults and their carers
2. all those 80 years of age and over
and frontline health and social care workers
3. all those 75 years of age and over
4. all those 70 years of age and over
and clinically extremely vulnerable individuals – *previously known as 'shielded'*
5. all those 65 years of age and over
6. all individuals aged 16 years to 64 years with underlying health conditions which put them at higher risk of serious disease and mortality – *includes homeless*
7. all those 60 years of age and over
8. all those 55 years of age and over
9. all those 50 years of age and over

*JCVI = Joint Committee on Vaccination and Immunisation



Data refreshed 07 Apr 2021 09:32

Bolton CCG First Doses by Priority Group

Individuals may appear in multiple groups therefore the groups should not be summed.

Priority Groups	First Dose	Individuals	% First Dose/ Individuals
Age 80+	12,075	12,698	95.1%
Age 75-79	9,703	10,201	95.1%
Age 70-74	13,612	14,513	93.8%
Age 65-69	13,083	14,319	91.4%
Age 60-64	15,038	16,962	88.7%
Age 55-59	17,431	20,386	85.5%
Age 50-54	17,580	21,805	80.6%
Clinically Extremely Vulnerable	21,448	24,267	88.4%
COVID19 at risk	27,869	35,364	78.8%

Total for Bolton registered patients

- **131,218 first doses**
- **22,086 second doses**

This data is from the National Immunisations System – it should be noted the ‘denominator’ or total in each cohort has received some challenge:

COVID19 at risk - Intended to represent cohort 6 ‘those with medical conditions ...’

Covid Vaccination Update

Key Messages this week (1)

Second doses

- Second doses have now started in earnest, at Bolton FT and at our local vaccination sites
- We have been assured second dose supply is guaranteed, with dates being provided for deliveries
- Some challenges matching Pfizer supply to 2nd dose locations
- Guidance on timing of second dose is between 77-84 days from first dose, but can be brought forward using clinical judgement (evidence suggests no earlier than 8 weeks unless clinical indication eg starting chemo)



Covid Vaccination Update

Key Messages this week (2)

Astrazeneca Announcement

Announcement made 7/4/21 by MHRA to **consider an alternative first dose vaccine** to AZ in those under 30 years. Those who have already had AZ under 30 and remained well should have the second dose as planned.

CAUSALITY HAS NOT BEEN PROVEN but links are 'firming up' and review ongoing so an informed discussion is required with patients and assessment of their underlying clot risk.

MHRA data: Over 20 mill doses AZ given; 79 blood clots after AZ upto 31/3/21- 4 per million risk at 5-14 days post AZ vaccine-idiosyncratic immune mediated reaction.

Risk benefit is in favour of all those 1-9 (and anyone over 30 years) in receiving either vaccine.

National Booking Service 1st dose AZ will be cancelled if <30 and they will be advised to discuss with GP/
Local vaccination sites risk benefit discussion and offer an alternative vaccine. Sites should be flexible to assist with this. Could still have AZ but need 'the right conversation' with a clinician first.